Biotech Companies in the News
HENDERSON, NV / ACCESSWIRE / December 13, 2018 / Here is a list of several Biotech companies in the news that could make investors profits heading into the holiday season.
We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Novavax, Inc. (NVAX), Celgene Corporation (CELG), Corcept Therapeutics Incorporated (CORT), and Tesaro, Inc. (TSRO).
According to the FDA, more than 72,000 people died from drug overdoses in 2017, including overdoses due to illicit drugs and prescription opioids. Biotech and CBD companies are both working on different solutions to this dire issue. Several of which we highlight below. The first on our list has just announced something that makes us even more intrigued than we already were. Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $8.614M, Share Price: $0.0218), a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, has developed a therapy that could help lessen the pain without the kinds of side effects many other opioid alternatives have. Their non-invasive easy to use ORTHOHALO™ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.
The announcement that peaked our interest is that ENDV has formed a partnership with US Authentic Trading Company (USAT) to act as the exclusive partner to assist with facilitating a relationship between the Company and China. China has been dealing with opioids since the 1600s, all the way back to the Opium wars. This market added to the already robust US market makes ENDV one of the most enticing opioid alternative plays on the market.
____
Novavax, Inc. (NVAX) (Market Cap: $949.468M, Share Price: $2.48) recently announced several key management promotions while the company pushes its lead clinical programs into commercial stage. The company is pushing their ResVax and NanoFlu programs towards licensure.
____
At the recent American Society of Hematology (ASH), Celgene Corporation (CELG) (Market Cap: $49.577B, Share Price: $70.90) presented extremely promising data for its liso-cel treatment for chronic lymphocytic lymphoma (CLL), a cancer of the blood. 81 % of patients responded to the treatment, and 43% showed a complete response. Liso-cel is a CAR-T gene therapy, which in a nutshell involves transforming a patient's immune cells to make them more effective at targeting cancers.
____
Corcept Therapeutics Incorporated (CORT) (Market Cap: $1.969B, Share Price: $17.05) a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, just announced that it dosed the first patient in the Phase 3 trial of relacorilant to treat patients with Cushing's syndrome.
____
Tesaro, Inc. (TSRO) (Market Cap: $4.092B, Share Price: $74.31) received a buyout offer from GlaxoSmithKline PLC. GSK said it would buy cancer-focused drug company Tesaro Inc. for about $4.16 billion, positioning the health-care giant in a promising, but fiercely competitive, area of medicine. Britain's Glaxo agreed to pay $75 a share in cash for the Waltham, Mass.-based company, a premium of 61% on its closing price Friday. The acquisition hands Glaxo Tesaro's ovarian cancer drug Zejula, which went on sale in the U.S. and Europe last year.
Legal Disclaimer:
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve month agreement, and can be canceled at anytime by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communications, LLC
